Description
Springer Macromolecular Anticancer Therapeutics 2010 Edition by L. Harivardhan Reddy Patrick Couvreur
In spite of the development of various anticancer drugs the therapy of cancer has remained challenging for decades. The current therapy of cancer is overwhelmed because of the inability to deliver therapeutics to all regions of a tumor in effective therapeutic concentrations intrinsic or acquired resistance to the treatment with currently available agents via genetic and epigenetic mechanisms and toxicity. As a result cancer therapy using conventional therapeutics and different types of treatment regimens using this therapeutics has not led to a convincing survival benefit of the patients. In this context Macromolecular therapeutics offer several advantages over conventional low molecular therapeutics by various ways such as enable the use of larger doses of these agents by limiting the toxicity by enhanced permeability and retention into tumors by tumor targeting using tumor-specific antibodies by specific inhibition of oncogenes using anticancer oligonucleotides etc. Cancer treatment using this macromolecular therapeutics has considerably improved the survival benefit for patients. As a result various macromolecular therapeutics are already commercialized or are under clinical development. Although we are far from a real magic bullet today looking at the pace of research and current success in this field of macromolecular therapeutics it appears that we are approaching a magic bullet for the efficient treatment of cancer. Thus we believe that the subject of this book is very timely and that the book will fill an unmet need in the market.This book is unique and assembles various types and aspects of macromolecular anticancer therapeutics for cancer therapy in one shell and conveys the importance of this interdisciplinary field to the broad audience. Thus in a nutshell this book details the basics of cancer and various therapeutic strategies such as those based on macromolecular therapeutics hence can become an important reference for practitioners oncologists medical pharmacologists medicinal chemists biomedical scientists experimental pharmacologists pharmaceutical technologists and particularly it can essentially become a handbook of macromolecular therapeutics for cancer therapy for graduates post-graduates and Ph.D. students in these fields. Table of contents : I. Synthetic polymer-based anticancer prodrugsJindrich Kopecek (Departments of Pharmaceutics and Pharmaceutical Chemistry and of Bioengineering University of Utah Salt Lake City Utah 84112) HPMA-anticancer drug conjugatesRichard B. Greenwald (Enzon Pharmaceuticals Inc. 20 Kingsbridge Road Piscataway New Jersey 00854)Poly(ethylene glycol)-anticancer drug conjugatesChun Li (Department of Experimental Diagnostic Imaging Box 59 The University of Texas M.D. Anderson Cancer Center1515 Holcombe Blvd. Houston TX 77030 USA)Poly(L-glutamic acid)-anticancer drug conjugatesII. Natural polymer-based anticancer prodrugsFelix Kratz (Department of Medical Oncology Clinical Research Tumor Biology Center Breisacher Strasse 117 D-79106 Freiburg Federal Republic of Germany) Protein-based anticancer conjugatesAndrew V. Schally (Endocrine Polypeptide and Cancer Institute Veterans Affairs Medical Center New Orleans Louisiana)Peptide and peptide hormone anticancer therapeuticsYoshiharu Machida (Department of Drug Delivery Research Hoshi University; 2-4-41 Ebara Shinagawa-ku Tokyo 142-8501 Japan)Chitosan and other polysaccharide anticancer conjugatesIII. Antibody-directed cancer therapyJohn R. DesjarlaisXencor Inc. CA 91016 United StatesEngineering of antitumor antibodiesVictor S. Goldmacher (ImmunoGen Inc. 128 Sidney Street Cambridge MA 02139-4239 USA)Antibody-anticancer drug conjugatesDavid M. Goldenberg (Garden State Cancer Center Center for Molecular Medicine and Immunology Belleville NJ 07109 USA.)Immunoconjugate and radioimmunoconjugate anticancer therapeutics Kenneth D. Bagshawe (Imperial College London Department of Medical Oncology Charing Cross Campus Fulham Palace Road London W6 8RF UK.)Antibody-directed enzyme prodrug anticancer therapeutics Paul M. Harari (University of Wisconsin Medical School and Comprehensive Cancer Center Madison WI 53792 USA.)EGFR-directed monoclonal antibodiesGabriel N. Hortobagyi (Department of Breast Medical Oncology The University of Texas M. D. Anderson Cancer Center Houston TX. usa)Her2/neu-directed antibodies John M. Kirkwood (Division of Hematology-Oncology Department of Medicine Hillman Cancer Center Pittsburgh PA 15232)CTLA-4-directed monoclonal antibodiesDario Neri (Department of Chemistry and Applied Biosciences Institute of Pharmaceutical Sciences ETH Zurich Switzerland)Antibodies directed to tumor vasculatureIV. Lipid-based anticancer prodrugsL. Harivardhan Reddy Patrick Couvreur (Physicochimie Pharmacotechnie et Biopharmacie Faculty of Pharmacy Universite Paris-Sud XI Chatenay-Malabry France)Lipid-based prodrugs of anti-metabolite anticancer agentsMitsuru Hashida (Department of Drug Delivery Research Graduate School of Pharmaceutical Sciences Kyoto University Sakyo-ku Kyoto 606-8501 Japan)Lipid-based prodrugs of non-anti-metabolite anticancer agentsV. Macromolecular nucleic acid therapeuticsErnst Wagner (Pharmaceutical Biology-Biotechnology Department of Pharmacy Ludwig-Maximilians-Universitaet Butenandtstr. 5-13 D-81377 Muenchen Germany)Macromolecular nucleic acid therapeuticsUwe Zangemeister-Wittke (Department of Pharmacology University of Bern Bern Switzerland.)Antisense oligonucleotidesBrett P. Monia (Isis Pharmaceuticals California 92008 USA)Therapeutic MicroRNAsMark A. Behlke (Integrated DNA Technologies Inc. Coralville IA 52241 USA)Therapeutic siRNAs